



**E Journal
of Cardiovascular
Medicine**

| Volume **4** | Issue **2** |

| April-June **2016** |

www.ejcvsmmed.org

E Journal of Cardiovascular Medicine

Echocardiographic findings among children with pectus excavatum


Esra Akyüz Özkan, Hashem E. Khosroshahi, Mahmut Kılıç, Bayram Metin, Halil İ. Serin

Hypertrophic obstructive cardiomyopathy and the cost of treatment

*Azam Jan, S. Mumtaz Anwar Shah, Somaiya Rehman,
Alessio Rungatscher, Naseer Ahmed, Giuseppe Faggian*

May the extraction of fresh thrombus prevent no-reflow phenomenon in coronary artery bypass surgery?

Ertan Demirdaş, Kivanç Atulgan, Ferit Çiçekçioğlu



E Journal of Cardiovascular Medicine
is a global e-journal targeting articles on:

- clinical cardiology,
- interventional cardiology,
 - arrhythmia,
- cardiovascular surgery,
- vascular & endovascular surgery,
- vascular biology

Editor-in-Chief

Prof. Öztekin Oto

FESC, FACC / President, Heart and Health Foundation of Turkey / Izmir / Turkey

Asistant Editors

Prof. Ali Kutsal

Sami Ulus Children Hospital Department of
Cardiovascular Sugery / Ankara / Turkey

Prof. Erdem Silistreli

Dokuz Eylül University, Department of Cardiovascular
Sugery / Izmir / Turkey

Prof. Bektaş Battaloğlu

İnönü University, Department of Cardiovascular Sugery
Malatya / Turkey

Dr. Onur Saydam

Karaman State Hospital Cardiovascular Surgery
Karaman / Turkey

Dr. Emre Doğan

Trabzon Ahi Evren Cardiovascular Surgery Hospital
Trabzon / Turkey

Dr. Taylan Adademir

Kartal Koşuyolu Resarch Hospital / Istanbul / Turkey

Owner

© TÜSAV Heart and Health Foundation of Turkey

Administration Office

Şair Eşref Bulvarı, 1402 Sk. No. 2/2 Özbaş Apt.
Alsancak - Izmir / Turkey
Tel: + 90 232 464 19 63 / Fax: +90 232 464 24 70
e-mail: info@oztekinoto.com | info@tksv.org

Publishing Coordinator

Hüseyin Kandemir

huseyin@medikalakademi.com.tr

Publisher

Medikal Akademi Yayıncılık ve Prodüksiyon Tic. Ltd. Sti.
Halaskargazi Cad. No: 172, D: 134 - Şişli / İstanbul
Tel: +90 537 309 29 55, Faks: (0212) 233 90 61
www.medikalakademi.com.tr/hizmetlerimiz

International Scientific Advisory Board

Prof. Harald Kaemmerer

German Heart Centre / Munich / Germany

Prof. Marko Turina

University Hospital of Zurich / Zurich / Switzerland

Prof. Frank W. Selke

Chief of Cardiothoracic Surgery at Brown Medical School
Rhode Island / USA

Prof. Joseph E. Bavaria

Hospital of the University of Pennsylvania
Philadelphia / USA

Prof. Fausto Pinto

Director of Lisbon Cardiovascular Institute / Portugal
& President of the European Society of Cardiology

Prof. Lazar Davidovic

Belgrade Medical School Cardiovascular Surgery
Belgrade / Serbia

Prof. Stephan Schueler

Tyne Freeman Hospital, Department for Cardiothoracic
Surgery Newcastle / United Kingdom

Prof. Piotr Kasprzak

University Hospital Regensburg, Director of Vascular
Surgery / Regensburg / Germany

Prof. Jose Luis Pomar

Hospital Clinico de Barcelona, Department of
Cardiovascular Sugery / Barcelona / Spain

Prof. Mohamed Moustafa Abdelaal

*Kafrelsheikh University Hospital, Cardiothoracic surgery and
General Director / Kafr El Sheikh / Egypt*

Assoc. Prof. Barış Akça

*Inonu University School of Medicine, Department of
Cardiovascular Surgery / Malatya / Turkey*

Dr. Rezan Aksoy

*Siyami Ersek Training and Research Hospital,
Cardiovascular Surgery / Istanbul / Turkey*

Dr. Şafak Alpat

*Birmingham Children's Hospital Pediatric Cardiovascular
Surgery / Birmingham / UK*

Dr. Mustafa Aldemir

*Kocatepe University, Department of Cardiovascular
Surgery / Afyon / Turkey*

Dr. Elena Zapata-Arriaza

*Hospital Universitario virgen del Rocío, Instituto de
biomedicina de Sevilla, Vascular Medicine / Sevilla / Spain*

Dr. Mehmet Atay

*Bakırköy Sadi Konuk Research Hospital, Cardiovascular
Surgery / Istanbul / Turkey*

Assoc. Prof. Hakan Aydın

*Sami Ulus in Ankara Training and Research Hospital,
Cardiovascular Surgery / Ankara / Turkey*

Assoc. Prof. Ahmet Çağrı Aykan

*Ahi Evren University of Health Sciences, Thoracic and
Cardiovascular Surgery / Trabzon / Turkey*

Assoc. Prof. Vedat Bakuy

*Bakırköy Sadi Konuk Training and Research Hospital,
Cardiovascular Surgery / Istanbul / Turkey*

Dr. Stefano Bartoli

*ASL Roma2, Cardiovascular Surgery
Rome / Italy*

Assoc. Prof. Elif Börekçi

*Bozok University Research and Application Hospital,
Internal Medicine / Yozgat / Turkey*

Dr. Tomasa Centella

*Hospital Ramón y Cajal, Cardiovascular Surgery
Madrid / Spain*

Assoc. Prof. Ahmet Çalışkan

*Dicle University School of Medicine, Cardiovascular Surgery
Diyarbakır / Turkey*

Dr. Gökhan Çavuşoğlu

*Ahi Evren University of Health Sciences, Thoracic and
Cardiovascular Surgery, Radiology / Trabzon / Turkey*

Dr. Deniz Çevirme

*Kartal Koşuyolu Research and Education
Hospital, Cardiovascular Surgery / Istanbul / Turkey*

Prof. Ferit Çiçekçioğlu

*Bozok University, Training and Research Hospital,
Cardiovascular Sugery / Yozgat / Turkey*

Assoc. Prof. Ertan Demirdaş

*Bozok University Research and Application Hospital and
Cardiovascular Surgery / Yozgat / Turkey*

Assoc. Prof. Yüksel Dereli

*Necmettin Erbakan University, Meram Midical Faculty
Hospital, Cardiovascular Surgery / Konya / Turkey*

Assist.Prof. İnci Selin Doğan

*Karadeniz Technical University Faculty of Pharmacy
Pharmacology, Medicinal Chemistry / Trabzon / Turkey*

Dr. Vehbi Doğan

*Sami Ulus Training and Research Hospital, Pediatric
Cardiology / Ankara / Turkey*

Dr. Çağrı Düzyol

*Kocaeli Derince Education and Research Hospital
Cardiovascular Surgery / Kocaeli / Turkey*

Assoc. Prof. Hüseyin Ede

*Bozok University, Medical Faculty, Cardiovascular Surgery
Yozgat / Turkey*

Dr. İlker Ertuğrul

*Sami Ulus Training and Research Hospital, Pediatric
Cardiology / Ankara / Turkey*

Prof. Niyazi Görmüş

*Necmettin Erbakan University, Meram Medical Faculty
Hospital, Cardiovascular Surgery / Konya / Turkey*

Assist. Prof. Adem Güler

*Gulhane Military Medical Academy Department of
Cardiovascular Surgery / Ankara / Turkey*

Assoc. Prof. Mustafa Gülgün

*GATA Department of Pediatrics, Division of Pediatric
Cardiology / Ankara / Turkey*

Prof. Usama Ali M. Hamza

*Mansoura University Faculty of Medicine, Cardiothoracic
Surgery, Cardiovascular Surgery / Mansoura / Egypt /*

Dr. James B Hermiller

*St Vincent's Medical Group, Interventional Cardiology
Indianapolis / USA*

Dr. Akihiko Ikeda

*Tsukuba Medical Center Hospital, Cardiovascular
Surgery / Tsukuba / Japan*

Dr. Richard W Issitt

*Great Ormond Street Hospital, Cardiac Surgery -
Pediatric Cardiology / London / UK*

Dr. Mehmet Kalender

*Derince Training and Research Hospital, Cardiovascular
Surgery / Kocaeli / Turkey*

Dr. Ayşegül Karadeniz

*Ahi Evren University of Health Sciences, Thoracic and
Cardiovascular Surgery, Radiobiology / Trabzon / Turkey*

Assoc. Prof. Osman Kayapınar

*Duzce University, Medical Faculty Department of
Cardiology / Düzce / Turkey*

Assoc. Prof. Alper Kepez

*Marmara University Training and Research Hospital Cardiol-
ogy Clinic / Istanbul / Turkey*

Assoc. Prof. Yasir Khan Khan

*Ch. Pervaiz Elahi Institute of Cardiology, Cardiovascular Sur-
gery / Punjab / Pakistan*

Assoc. Prof. Levent Korkmaz

*Ahi Evren University of Health Sciences, Thoracic and
Cardiovascular Surgery / Trabzon / Turkey*

Assoc. Prof. Ulaş Kumbasar

*Hacettepe University Medical School Cardiovascular
Surgery / Ankara / Turkey*

Dr. Redha Lakehal

*Department of heart surgery, EHS Erriadh / Constantine
Algeria*

Dr. Wei-Chieh Lee

*Kaohsiung Chang Gung Memorial Hospital, Cardiology
Kaohsiung City / Tayvan*

Dr. José Luis Serrano Martínez

*University Hospital of Granada, Department of Internal
Medicine / Granada / Spain*

Assoc. Prof. Ümit Mentşe

*Ahi Evren University of Health Sciences, Thoracic and
Cardiovascular Surgery / Trabzon / Turkey*

Dr. Nooredin Mohammadi

*Iran University of Medical Sciences, Cardiology, Demand
for Health Care, Determinants of Health / Tehran / Iran*

Dr. Vinod Namana

*Maimonides Medical Center, Department of Medical
Research / New York / USA*

Dr. Silvio Nocco

Sirai Hospital, Department of Cardiology / Carbonia / Italy

Assoc. Prof. Zeynep Tuğba Özdemir

*Bozok University School of Medicine, Internal Medicine
Yozgat / Turkey*

Dr. Tanıl Özer

*Kartal Koşuyolu Yüksek İhtisas Research and Education
Hospital / Istanbul / Turkey*

Prof. Murat Özeren

*Mersin University Medical School, Cardiovascular
Surgery / Mersin / Turkey*

Assoc. Prof. Emre Özker

*Başkent University School of Medicine, Department of
Cardiovascular Surgery / Ankara / Turkey*

Dr. Abdullah Özyurt

*Mersin Maternity and Children Diseases Hospital, Pediatric
Cardiology / Mersin / Turkey*

Dr. Recep Oktay Peker

*Hacettepe University, Department of Cardiovascular Surgery
Ankara / Turkey*

Dr. Hikmet Sahratov

*Gülhane Education and Research Hospital, Department of
Cardiovascular Surgery / Ankara / Turkey*

Dr. Gonzalo Luis Alonso Salinas

*Marcelo Sanmartín of Hospital Universitario Ramón y Cajal
Madrid / Spain*

Dr. Stefano Salizzoni

*Città della Salute e della Scienza, Cardiac Surgery,
Cardiac Surgery / Turin / Italy*

Dr. Gökhan Sargın

*Adnan Menderes University Medical School, Internal
Medicine / Aydın / Turkey*

Dr. Mustafa Seren

*Ankara 29 Mayıs State Hospital and Cardiovascular
Surgery / Ankara / Turkey*

Prof. Erdem Silistreli

*Dokuz Eylül University, Department of Cardiovascular
Surgery / İzmir / Turkey*

Assoc. Prof. Ömer Tanyeli

*Necmettin Erbakan University, Meram Medical Faculty
Hospital, Cardiovascular Surgery / Konya / Turkey*

Dr. İlker Tekin

*Antalya Medicalpark Hospital, Cardiovascular Surgery
Antalya / Turkey*

Assist. Prof. Dinçer Uysal

*Isparta Süleyman Demirel University, Department of
Cardiovascular Surgery / Isparta / Turkey*

Dr. Olivier Villemain

*IM3C Necker-Enfants Malades, AP-HP, Université Paris
Descartes, Pediatric Cardiology, Radiology / Paris / France*

Dr. Mustafa Esat Yamaç

*Ahi Evren University of Health Sciences, Thoracic and
Cardiovascular Surgery / Trabzon / Turkey*

Assoc. Prof. Ali Ümit Yener

*Canakkale Onsekiz Mart University Medical Faculty,
Department of Cardiovascular Surgery / Çanakkale / Turkey*

Dr. Dilek Yeşilbursa

*Uludağ University, Medical Faculty, Department of
Cardiology / Bursa / Turkey*

Dr. Mustafa Yılmaz

*Sami Ulus Training and Research Hospital, Pediatric
Cardiology / Ankara / Turkey*

| Volume **4** | Number **2** | April-June **2016** |

Research Articles

Hypertrophic obstructive cardiomyopathy and the cost of treatment | 27

Azam Jan, S. Mumtaz Anwar Shah, Somaiya Rehman,
Alessio Rungatscher, Naseer Ahmed, Giuseppe Faggian

Echocardiographic findings among children with pectus excavatum | 33

Esra Akyüz Özkan, Hashem E. Khosroshahi, Mahmut Kılıç, Bayram Metin, Halil İ. Serin

Case Report

A rare existence of paragangliomas

Bilateral carotid body tumors: A case report | 41

Sadi Kaplan, Tuğba Avcı, Çetin Murat Songur, Cavit Ceylan

May the extraction of fresh thrombus prevent

no-reflow phenomenon in coronary artery bypass surgery? | 45

Ertan Demirdaş, Kıvanç Atılğan, Ferit Çiçekçioğlu

Hypertrophic obstructive cardiomyopathy and the cost of treatment

Azam Jan¹, S. Mumtaz Anwar Shah¹, Somaiya Rehman¹, Alessio Rungatscher²,
Naseer Ahmed², Giuseppe Faggian²

¹ Department of Cardiac Surgery, Rehman Medical Institute, Peshawer Pakistan

² Department of Surgery, Cardiac Surgery Division, University of Verona Medical School, Verona, Italya

Abstract

Objective: To evaluate the demographics of patients admitted with Hypertrophic Obstructive Cardio-Myopathy (HOCM) and the financial burden of this disease on the health care system.

Methods: The Healthcare Cost and Utilization Project (HCUP), sponsored by The Agency for Healthcare Research and Quality's (AHRQ), includes the largest collection of longitudinal hospital care data in the United States of America. HCUP creates the National In-patient Sample data (NIS) to help conduct national and regional analyses of inpatient care. Using the NIS data (2013), we performed a retrospective cohort study that involved patients who were admitted and treated for HOCM.

Results: A total of 2605 patients were admitted for the principal diagnosis of HOCM in 2013. Mean hospitalization was 4.9 days. In our total population, 33% of the patients were above 64 years of age. Mean cost of admission was 25,433\$. Private insurance and Medicare or Medicaid paid for 43% and 47% admissions respectively. 76%, 3.5%, 4.6% and 13% patients were discharged to routinely home, another short term hospital, nursing home and for home health care, respectively.

Conclusions: HOCM admissions are relatively uncommon but effects all ages. Most of these patients were treated at a private hospital, and the hospital costs were very high. Large number of patients required rehabilitation services after discharge which increase financial burden on health care system.

Keywords: Healthcare research, hypertrophic obstructive cardiomyopathy, nursing and rehabilitation, healthcare cost

Acknowledgements: The authors acknowledge all of the HCUP Data Partners that contribute to HCUP. List of these State organizations can be accessed at (www.hcup-us.ahrq.gov/hcupdatapartners.jsp).

Jan A, Anwar Shah M., Rehman S., Rungatscher A., Ahmed N, Faggian G. Hypertrophic obstructive cardiomyopathy and the cost of treatment. EJCM 2016; 04 (2): 27-32. Doi: 10.15511/ejcm.16.00227.

Introduction

Hypertrophic cardiomyopathy (HCM) is a complex but relatively common form of genetic heart muscle disease and has been under investigation since more than last 50 years.¹⁻⁴ Prevalence of the disorder in the general population is estimated to be 0.2%⁵. It is often identified by clinicians later on in the disease course. A subset of patients with HCM has hypertrophic obstructive cardiomyopathy (HOCM), in which systolic septal bulging into the LVOT, malposition of the anterior papillary muscle, with enlarged posterior mitral leaflet and hyperdynamic LV contraction and drag forces, through a Venturi effect, provoke systolic anterior motion of the anterior leaflet of the mitral valve (SAM), contributing to the creation of the LVOT gradient.⁶ HOCM is the most common cause of heart-related sudden death in people under 30 years of age⁷, and it can also be responsible for exercise intolerance at almost any age. HOCM occurs in both genders with female dominance and has been reported in many races.⁸ Although HOCM is a chronic disease without a known cure, a number of treatments options are now available to alter its course.

In 2014, U.S. health care spending increased 5.3 percent to reach \$3.0 trillion, or \$9,523 per person. The share of the economy devoted to health care spending has been rising to 17.3 percent in 2013. Further spending for hospital care increased by 3.5 percent in 2013. Spending growth for freestanding home health care agencies accelerated in 2014, increasing to \$83.2 billion. Similarly total private health insurance expenditures increased 4.4 percent (33 percent of total health care spending) to \$991.0 billion in 2014, faster than the 1.6 percent growth in 2013 along with nursing home and rehabilitation expenses.

In this age of exponentially rising costs of health care, we wanted to assess the management cost of patients admitted to hospitals with the lethal diagnosis of Hypertrophic Obstructive cardiomyopathy (HOCM). We wanted to further look at their demographics and quantify the financial burden of this disease on the individual patient and health care system across USA.

Methods

The Healthcare Cost and Utilization Project (HCUP),

sponsored by The Agency for Healthcare Research and Quality's (AHRQ), includes the largest collection of longitudinal hospital care data in the United States of America. HCUP creates the National Inpatient Sample (NIS) to help conduct national and regional analyses of inpatient care. Using the NIS (2013), we performed a retrospective cohort study that involved patients who were admitted and treated for Hypertrophic Obstructive Cardiomyopathy. To identify these patients we used ICD-9-CM principal diagnosis code 425.11. ICD-9-CM stands for the "International Classification of Diseases - 9th revision - Clinical Modification." The "principal diagnosis" is that condition established after study to be chiefly responsible for occasioning the admission of the patient to the hospital for care. The principal diagnosis is always the reason for admission. The unit of analysis for HCUP data is the hospital discharge (i.e., the hospital stay), not a person or patient. This means that a person who is admitted to the hospital multiple times in one year will be counted each time as a separate "discharge" from the hospital.

Using statistical analysis we compared the demographics, geographical distribution and the cost of treating these patients. Unweighted, HCUP contains data from more than 7 million hospital stays each year. Weighted, it estimates more than 36 million hospitalizations nationally taken from more than 4,000 HCUP participating hospitals.

Results

A total of 2605 patients were admitted for the principal diagnosis of HOCM in 2013. Mean Length of hospital stay was 4.9 days. 55% of the patients were women. 33% of the patients were above 64 years of age, whereas 18% patients were aged below 45 (**Table 1**).

Hospital "charges" is the amount the hospital charged for the entire hospital stay. It does not include professional (MD) fees. "Costs" tend to reflect the actual costs of production, while charges represent what the hospital billed for the case. Total charges were converted to costs using cost-to-charge ratios based on hospital accounting reports from the Centers for Medicare and Medicaid Services (CMS). Mean cost of admission was 25,433\$ and Median cost of admission 19,422 \$. But the mean hospital charge for the admission was

Table 1-1: Outcomes for hypertrophic obstructive cardiomyopathy ICD-9-CM code 425.11

Variables		Total number of discharges		Charges \$ (mean)	Costs, \$ (mean)	Routine Discharge
All discharges		2,605	100.00%	88,646	25,433	76.39%
Age group	1-17	*	*	82,642	33,230	*
	18-44	470	18.04%	117,034	32,057	89.36%
	45-64	1,165	44.72%	86,340	24,942	78.97%
	65-84	790	30.33%	81,157	22,976	65.19%
	85+	80	3.07%	41,650	8,993	*
Sex	Male	1,170	44.91%	87,848	25,628	82.91%
	Female	1,435	55.09%	89,287	25,276	71.08%
Payer	Medicare	955	36.66%	73,647	19,681	64.40%
	Medicaid	260	9.98%	71,918	18,967	76.92%
	Private insurance	1,120	42.99%	103,823	31,370	82.59%
	Uninsured	125	4.80%	*	*	88.00%
	Other	*	*	61,735	21,848	*
	Missing	*	*	*	*	*
Median income for zipcode	Low	625	23.99%	97,783	27,506	81.60%
	Not low	1,915	73.51%	86,378	24,938	74.41%
	Missing	65	2.50%	64,491	19,387	*
Owner	Government	320	12.28%	68,846	20,961	82.81%
	Private, not-for-profit	2,140	82.15%	91,094	26,608	75.23%
	Private, for-profit	145	5.57%	97,738	18,687	79.31%
Location/teaching status	Rural	85	3.26%	24,175	9,567	*
	Urban nonteaching	405	15.55%	95,875	23,499	74.07%
	Urban teaching	2,115	81.19%	89,921	26,478	77.54%

Weighted national estimates from HCUP National Inpatient Sample (NIS), 2013. Statistics based on estimates with a relative standard error (standard error / weighted estimate) greater than 0.30 or with standard error = 0 are not reliable. These statistics are suppressed and are designated with an asterisk (*). Significant at $p < .05$

88,646 \$ and median Hospital charge 58,460\$. Highest charges were for the patients with the following factors below 44 years of age, private insurance being the payer, West region of USA and Pacific census division. 47% of admissions were paid by either Medicare or Medicaid and 43 % of admissions were paid by private. 5% patients were uninsured. 82% patients were taken care at private hospitals. 74% patients belonged to a high income area in the country (Table 1).

Bedsize categories are based on hospital beds and are specific to the hospital's location and teaching status. The definitions of small, medium, and large hos-

pitals vary by region . A hospital is considered to be a teaching hospital if the American Hospital Association (AHA) Annual Survey indicates it has an American Medical Association approved residency program, is a member of the Council of Teaching Hospitals (COTH), or has a ratio of full-time equivalent interns and residents to beds of 25 or higher. Teaching hospitals took care of 82% of these admissions (Figure 1).

Discharge status indicates the disposition of the patient at discharge from the hospital, e.g., routine (home), to another short term hospital, to a nursing home, to home health care, or against medical advice

Table 1-2: Outcomes for hypertrophic obstructive cardiomyopathy ICD-9-CM code 425.11

Variables		Total number of discharges		Charges \$ (mean)	Costs, \$ (mean)	Routine Discharge
Bedsize	Small	245	9.40%	72,282	22,155	73.47%
	Medium	445	17.08%	86,702	24,507	67.42%
	Large	1,915	73.51%	91,305	26,094	78.85%
Region	Northeast	570	21.88%	90,831	22,463	62.28%
	Midwest	*	*	83,300	29,230	*
	South	805	30.90%	74,287	21,079	82.61%
	West	405	15.5%	134,577	31,947	72.84%
Census division	New England	*	*	59,281	21,945	*
	Middle Atlantic	420	16.12%	102,099	22,648	64.29%
	East North Central	*	*	85,936	24,199	*
	West North Central	*	*	80,727	34,139	*
	South Atlantic	430	16.51%	56,105	16,775	83.72%
	East South Central	*	*	*	33,259	*
	West South Central	225	8.64%	74,986	21,184	84.44%
	Pacific	120	4.61%	105,473	27,079	83.33%
		285	10.94%	152,040	34,867	68.42%

Weighted national estimates from HCUP National Inpatient Sample (NIS), 2013. Statistics based on estimates with a relative standard error (standard error / weighted estimate) greater than 0.30 or with standard error = 0 are not reliable. These statistics are suppressed and are designated with an asterisk (*). Significant at $p < .05$



(AMA). Increase in age has an inverse relation with routine discharge i.e. from 90% to 65% decline as age goes from 18 to 85 years. (Table 1) 20% of the patients require further institutional care after discharge (Figure 2).

Conclusion

Our study presents valuable real-world information regarding HOCM from the largest available

inpatient care database. HOCM admissions are relatively uncommon but affect all ages. Its admissions are relatively more common in the South of USA and in high income population.

Most of these patients were treated at a private hospital, and the hospital charges were very high. Large number of patients required care after discharge adding to the cost of already very expensive treatment.



References

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. *Br. Heart J.* 1958;20:1-8
2. Braunwald E, Lambrew CT, Rockoff SD, Ross J, Jr., Morrow AG. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. *Circulation.* 1964;30:SUPPL 4:3-119
3. Maron BJ, Bonow RO, Cannon Iii RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology, and therapy. *N. Engl. J. Med.* 1987;316:780-789
4. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. *J. Am. Coll. Cardiol.* 1995;26:1699-1708
5. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. *N. Engl. J. Med.* 1997;336:775-785
6. Vatasescu R, Evertz R, Mont L, Sitges M, Brugada J, Berruezo A. Biventricular / left ventricular pacing in hypertrophic obstructive cardiomyopathy: An overview. *Indian pacing and electrophysiology journal.* 2012;12:114-123
7. Colan SD. Hypertrophic cardiomyopathy in childhood. *Heart failure clinics.* 2010;6:433-444, vii-iii
8. Terauchi Y, Kubo T, Baba Y, Hirota T, Tanioka K, Yamasaki N, Furuno T, Kitaoka H. Gender differences in the clinical features of hypertrophic cardiomyopathy caused by cardiac myosin-binding protein c gene mutations. *J. Cardiol.* 2015;65:423-428

Received: 17/04/2016

Accepted: 11/05/2016

Published: 20/06/2016

Disclosure and conflicts of interest:

Conflicts of interest were not reported.

Corresponding author:

Dr. Naseer Ahmed

Mail: dr.naseer99@gmail.com

Echocardiographic findings among children with pectus excavatum

Esra Akyüz Özkan¹, Hashem E. Khosroshahi², Mahmut Kılıç³, Bayram Metin⁴, Halil İ. Serin⁵

¹) Department of Pediatrics, Bozok University Medical Faculty, Yozgat, Turkey

²) Department of Pediatric Cardiology, Bozok University Medical Faculty, Yozgat, Turkey

³) Department of Public Health, Bozok University Medical Faculty, Yozgat, Turkey

⁴) Department of Thoracic Surgery, Bozok University Medical Faculty, Yozgat, Turkey

⁵) Department of Radiology, Bozok University Medical Faculty, Yozgat, Turkey

Abstract

Objective: Pectus excavatum (PE) is characterized by the posterior displacement of inferior sternum and adjacent cartilages and is the most common congenital chest wall deformity. We aimed to investigate right and left ventricular functions and its correlation with pectus severity index in children.

Methods: Echocardiography was performed in 32 children with PE and 40 healthy controls. The following parameters were monitored: Left and right ventricular (LV, RV) ejection fraction (EF), ejection time (ET), stroke volume (SV), shortening fraction (SF), mitral and tricuspid early (E) and late (A) ventricular filling velocities and deceleration time (DT), median pulmonary arterial pressure (PAPm), aorta and pulmonary acceleration time (Ao-AT, PA-AT), RV work index (RVWI), isovolumetric myocardial acceleration (IVMA), and LV pulmonary ejection period (PEPLV). To assess the severity of pectus, Haller Index (HI) was calculated by thorax computed tomography.

Results: There was no significant difference regarding averages of the body surface area (BSA) between the groups. The arithmetic averages of the EF-Left, ET-Left, ET-Right, SV-Left, TV-DT, PA-AT, and PEPLV were higher in children with PE than in controls, but SF-Left, SF-Right, MV-A, and IVMA were found to be lower. Haller Index (HI) value in children with PE was 2.00-4.93(2.62±0.56). We failed to demonstrate any statistically significant relationship between the cardiac data of children with PE and HI.

Conclusion: Despite the fact that most children had only a mild or moderate form of PE, the RV and LV functions were affected.

Keywords: Children, echocardiography, left ventricular function, pectus excavatum, right ventricular function

Introduction

Pectus excavatum (PE), or funnel chest, is one of the most common congenital skeletal deformities. Characterized by an inward depression of the sternum, it is seen in approximately 1 in every 400 male births.^[1] Pectus anomalies can be diagnosed at an early age and are three times more common in boys.^[2]

The etiology of PE is unknown; it is often seen as isolated anomalies. The primary deformity is dystrophic costal cartilage growth along with the sternum depression. Pectus deformity manifests as subtle abnormalities associated with collagen morphology of children's costal cartilages, but the causal significance of this is not precisely known. Approximately one-third of cases have a positive family history of chest wall deformity.^[3]

In addition to cosmetic problems, posterior angulation of the sternum and rib cartilages may cause changes in the rotation and location of the heart and may lead to cardiorespiratory function abnormalities.^[4] Some studies demonstrated a significant compromise of cardiac or pulmonary functions^[5,6], whereas other studies showed no change in cardiac functions.^[7] Decreased cardiac output, mitral valve prolapse (MVP), and dysrhythmias are considered the primary cardiac effects of PE. Compression of the heart, in particular of the right atrium and ventricle by the chest wall, results in incomplete filling and decreased stroke volume, and eventually in decreased cardiac output.^[5,6] Similarly, compression of the right ventricle (RV) by the chest wall can lead to patient symptoms including dyspnea and chest pain with exertion.^[8,9] The chest deformity may also cause compression on the vena cava inferior.^[10]

There are conflicting studies about the effects of PE on cardiopulmonary functions. Malek et al.^[11] demonstrated that the oxygen pulse and maximum oxygen uptake were low in PE patients. Yalamanchili et al.^[12] showed in a case with PE that SV-Rt (RV stroke volume) was reduced. Haller et al.^[13] reported that cardiopulmonary functions improved after surgery. Conversely, it is reported that since these patients do not participate in social events and sports, the cardiopulmonary symptoms are related to psychological disorders.^[14,15]

We aimed to investigate right and left ventricular (LV) functions more comprehensively and determine their correlation with pectus severity index in children with PE.

Materials and methods

We studied 32 pediatric patients selected randomly from those with PE but without any other congenital anomaly or disease and 40 healthy subjects. Individuals with pulmonary, renal diseases and a history of diabetes, hypertension, obesity or other systemic diseases were excluded. A full history was taken and a complete physical examination was performed by the same physician. The body height and weight of all children were recorded. Body surface area (BSA) was calculated by Mosteller formula.^[16]

At the time of the other tests, an electrocardiogram was recorded for all patients. Transthoracic echocardiography was performed by a single experienced pediatric cardiologist and the following parameters were monitored:

Ejection fraction (EF) was calculated using the standard dimension cubed formula:

$EF = (LVDD3 - LVDS3) / LVDD3$, where LVDD and LVDS stands for LV dimension in diastole and systole respectively.

SV was calculated as: $SV = (LVOT / 2)^2 \times VTIAo \times 3.141$. The LV outflow tract (LVOT) diameter was measured at the base of the aortic leaflet at the parasternal long axis view in echocardiography. Time velocity integral for aortic valve (VTIAo) was obtained with continual wave Doppler immediately below the aortic valve in the apical long axis view.

Aortic Doppler was used to calculate the time intervals—the pre-ejection period (PEP), i.e. the time interval from Q wave of ECG to the onset point of aortic Doppler flow, and the Q-T offset interval, i.e. the time interval from Q wave of ECG to the offset point of aortic Doppler flow.

Mitral and tricuspid early (E) and late (A) filling velocities were recorded from the apical four-chamber view with the pulse-wave Doppler during diastole. E,

A, and deceleration time (DT) were used as both ventricular diastolic function parameters. Ejection time (ET) was calculated from the beginning to the end of the pulmonary and aortic flow.

Isovolumetric myocardial acceleration (IVMA) was calculated by dividing isovolumetric volume (IVV) by the time interval from onset of IVV to the time at peak velocity of this wave.

Mean pulmonary arterial pressure (PAPm) = 0.65 × (PAPs + 0.55);

RV work index (RVWI) = 0.136 × (PAPm - RAP) × SV;

Shortening fraction (SF) = LV end-diastolic - LV end-systolic / LV end-diastolic diameter;

Haller Index (HI) = A / B where A stands for transverse diameter at the deepest level of deformity, and B for anterior-posterior diameter of the same level. An HI <2.5 was considered as mild, HI = 2.5-3.2 as moderate, and HI >3.2 as severe deformity. The A and B diameters of our PE subjects were calculated by thorax computed tomography.

Statistical analyses

The statistical analyses were performed using Statistical Package for the Social Sciences (SPSS). Data were analyzed by independent t test and Analysis of covariance (ANCOVA) test. The arithmetic means of cardiac measurements of children with pectus deformity and of the control group were compared according to independent t test. Important parameters between groups as determined by independent t test were subjected to ANCOVA multiple analyses. Cardiac parameters can be affected by age and the BSA, so these two factors are taken as covariate variables to multi ANCOVA analysis. In ANCOVA analysis, pectus and control group were taken as fixed factors; age and BSA were taken as covariate variables. HI arithmetic average and correlation values of HI and the cardiac parameters were investigated.

Results

32 children (23 male, 9 female) with PE deformity and 40 (17 male, 23 female) healthy controls were

included in the study. There was no significant difference regarding average of the age and body surface area (BSA) between the groups.

The arithmetic averages of the EF-Lft, ET-Lft, ET-Rt, SV-Lft, TV-DT, PA-AT and PEPLV were found to be higher in children with PE than in controls (**Table 1**).

ANCOVA analysis revealed that, when age and BSA were taken as covariate variables and pectus and control group as fixed factors, all parameters mentioned above were found to be statistically significant (**Table 2**).

The arithmetic average of the SF-Lft, SF-Rt, MV-A and IVMA were found to be lower in children with PE than in controls (**Table 1**). According to ANCOVA analysis, when age and BSA were taken as covariate variables and pectus and control group as fixed factors, all parameters except for MV-A were found to be statistically significant. These differences in SF-Lft of 48.5%, in SF-Rt of 19.4%, in IVMA of 8.2%, and in EF-Rt of 7.2% can be attributed to pectus disease (**Table 2**).

HI value among children with PE ranged between 2.00 and 4.93 (2.62±0.56). Of the total of 32 patients with PE, 14 showed mild, 15 moderate, and 3 severe deformities. We found no statistically significant correlation between HI and cardiac parameters among children with PE.

Discussion

Although PE can be viewed as a slight problem, it can lead to much more than a cosmetic deformity. Volume reduction and cardiac chest compression can lead to a reduction in cardiopulmonary function and physical capacity. Symptoms rarely appear in early childhood but increase with age.^[17] The chest wall elasticity decreases, stiffness increases, heart deviation to the left decreases, and pressure on the heart increases, with corresponding increase of symptoms with age in PE patients.

RV dysfunction can be seen in patients with PE. Ventricles share a common septum and are within the same pericardial cavity. This relationship between the ventricles also causes similar changes in both systolic and diastolic functions.^[18] The compression on the RV

also can cause changes in the size and function of the LV. Cardiac output and SV were demonstrated to be reduced in pectus patients and improved after corrective surgery.^[19] Gürsu et al.^[20] found lower EF-Lft in the PE group and also revealed that there was an inverse relationship between EF-Lft and SF by HI. EF-Lft and SF-Lft were significantly reduced by increasing HI, but LV end-diastolic volume showed no significant change.

Another study^[21] demonstrated, using transesophageal echocardiography, that RV end-diastolic size and EF-Lft were increased after the surgery. Bawazir et al.^[22] showed that after the pectus corrective surgery, the LV cardiac output and index improved and was maintained thereafter. In their meta-analysis, Malek et al.^[23] indicated that the LV function was increased after surgery. Lyons et al.^[24] reported the pattern of the RV pressure in

Table 1-1. Echocardiographic findings of children with pectus excavatum compared to the control group

Cardiac parameters	Groups	N	Mean	Std. Deviation	t	p
Age	Pectus	32	11.16	3.15	-1.215	.228
	Control	40	12.08	3.21		
BSA	Pectus	32	1.248	.301	-1.435	.156
	Control	40	1.359	.347		
ET-Lft (msec)	Pectus	32	292.968	21.159	7.275	<.001
	Control	40	245.800	30.898		
ET-Rt (msec)	Pectus	32	317.161	26.303	11.171	<.001
	Control	40	241.100	30.006		
SV-Lft (ml)	Pectus	32	61.398	20.000	2.541	.114
	Control	40	65.989	23.084		
SV-Rt (ml)	Pectus	32	66.545	22.769	.334	.739
	Control	40	64.700	23.655		
SF-Lft (%)	Pectus	32	.222	.074	-8.243	<.001
	Control	40	.342	.049		
SF-Rt (%)	Pectus	32	.289	.092	-4.206	<.001
	Control	40	.387	.101		
MV-A (cm/sec)	Pectus	32	53.000	9.837	-2.000	.049
	Control	40	58.600	13.163		
MV-E (cm/sec)	Pectus	32	103,56	11,528	-.244	.808
	Control	40	104,28	12,926		
MV-DT (msec)	Pectus	32	207,88	54,289	1.306	.196
	Control	40	192,50	45,608		

SD: Standard Deviation. BSA: Body surface area, EF: Ejection fraction, ET: Ejection time, SV: Stroke volume, SF: Shortening fraction, MV: Mitral valve, TV: Tricuspid valve, DT: Deceleration time, PAPm: median pulmonary arterial pressure, PA-AT: Pulmonary artery acceleration time, Ao: aorta, Acc: acceleration, RVWI: Right ventricular work index, IVMA: isovolumetric myocardial acceleration, PEPLV: Left ventricular pulmonary ejection period, Rt: right, Lft: left.

patients with PE. Peterson et al.^[25] found significant improvement in RV end-diastolic volume and EF-Rt and also increments in LV end-diastolic volume index and SV index after pectus surgery. Saleh et al.^[26] found that both EF-Lft and EF-Rt were lower and RV end-systolic volume was significantly higher in PE patients.

They did not detect any significant correlation be-

tween the EF-Rt and EF-Lft and pectus index. They also did not find any differences in EF-Lft, SF-Lft, aorto-pulmonary circulation time, or pulmonary flow indices between PE patients and controls. They suggested that the high end-systolic volume caused reduced EF-Rt. To assess ventricular global functions, EF is the commonly used measurement. Reduced EF generally reflects decreased contractility. Because EF depends on loading

Table 1-2. Echocardiographic findings of children with pectus excavatum compared to the control group

Cardiac parameters	Groups	N	Mean	Std. Deviation	t	p
TV-A (cm/sec)	Pectus	32	47,84	10,913	-1.595	.117
	Control	40	51,48	7,646		
TV-E (cm/sec)	Pectus	32	82,97	15,233	-1.476	.145
	Control	40	87,78	12,413		
TV-DT (msec)	Pectus	32	214.938	59.976	1.993	.050
	Control	40	189.875	46.765		
PAPm (mm/Hg)	Pectus	32	12,996	3,526	.475	.638
	Control	40	12,700	,000		
PA-AT (msec)	Pectus	32	129.513	19.639	3.252	.002
	Control	40	115.600	16.400		
PA-Acc	Pectus	32	8.912	2.072	-1.075	.286
	Control	40	9.473	2.301		
Ao-Acc	Pectus	32	13,289	4,152	-.377	.708
	Control	40	13,616	3,102		
Ao-AT (msec)	Pectus	32	94,067	17,031	1.203	.233
	Control	40	89,425	15,152		
RVWI (gm-m/m2)	Pectus	32	4.181	2.011	1.189	.238
	Control	40	4.721	1.839		
IVMA (cm/msec2)	Pectus	32	.067	.027	-2.374	.020
	Control	40	.083	.029		
PEPLV (msec)	Pectus	32	71.813	12.238	3.195	.002
	Control	40	63.050	11.001		

SD: Standard Deviation. BSA: Body surface area, EF: Ejection fraction, ET: Ejection time, SV: Stroke volume, SF: Shortening fraction, MV: Mitral valve, TV: Tricuspid valve, DT: Deceleration time, PAPm: median pulmonary arterial pressure, PA-AT: Pulmonary artery acceleration time, Ao: aorta, Acc: acceleration, RVWI: Right ventricular work index, IVMA: isovolumetric myocardial acceleration, PEPLV: Left ventricular pulmonary ejection period, Rt: right, Lft: left.

Table 2. The cardiac measurements were analyzed by ANCOVA according to age, BSA vs. groups

Cardiac measurements	Variables	F	Sig.	Partial Eta Squared	R2	Adj. R2
EF-Rt (%)	Age	1.56	.216			
	BSA	.48	.490			
	Groups	5.29	.025	.072	.108	.069
ET-Lft (msec)	Age	4.12	.046	.058		
	BSA	.35	.554			
	Groups	63.06	<.001	.485	.507	.485
ET-Rt (msec)	Age	.249	.620			
	BSA	.222	.629			
	Groups	130.62	<.001	.661	.662	.647
SF-Lft (%)	Age	.16	.694			
	BSA	.03	.867			
	Groups	63.47	<.001	.483	.495	.472
SF-Rt (%)	Age	2.10	.152			
	BSA	.75	.391			
	Groups	16.34	<.001	.194	.233	.199
MV-A (cm/sec)	Age	5.11	.027	.070		
	BSA	4.29	.042	.059		
	Groups	3.84	.054	.054	.121	.082
TV-DT (msec)	Age	2.022	.160			
	BSA	.590	.445			
	Groups	4.527	.037	.062	.093	.053
PA-AT (msec)	Age	1.178	.282			
	BSA	.052	.820			
	Groups	12.229	<.001	.154	.173	.136
PEPLV (msec)	Age	3.525	.065			
	BSA	1.319	.255			
	Groups	11.268	<.001	.142	.182	.145
IVMA (cm/msec ²)	Age	1.501	.225			
	BSA	.579	.449			
	Groups	6.005	.017	.082	.101	.061

Groups: Children with Pectus and normal children. **BSA:** Body surface area. **EF:** Ejection fraction, **ET:** Ejection time, **SF:** Shortening fraction, **MV:** Mitral valve, **TV:** Tricuspid valve, **DT:** Deceleration time, **PA-AT:** Pulmonary artery acceleration time, **VMA:** isovolumetric myocardial acceleration, **PEPLV:** Left ventricular pulmonary ejection period, **Rt:** right, **Lft:** left.

conditions, and changes in preload and afterload affect the contractility, EF is not considered an accurate measurement^[27, 28] Similarly, regional EF is also load-dependent and does not reveal contractility.^[29] IVMA is a measurement of ventricular contractile function that is unaffected by preload and afterload changes in a physiological range. Vogel et al.^[30] showed in a pig model that IVMA was less load-dependent than EF.

They demonstrated that IVMA was unchanged with the decrease in the preload and increase in the afterload conditions and therefore can be used to assess RV myocardial function. In the current study, EF-Rt was found to be significantly lower in pectus children than in controls, although EF values were within normal limits and EF-Lft was similar between the two groups. At the same time, IVMA was found to be lower in patients with pectus than in controls, showing that RV contractility is reduced in pectus children. RV functions using quantitative echocardiographic parameters were assessed by Gurkan et al.^[31] They reported that the preoperative tricuspid annular plane systolic excursion, SV, and IVMA values were significantly improved in the postoperative period.

We showed that SF-Rt and SF-Lft were lower in

pectus children than in controls. A decrease in the SF usually precedes a noticeable decrease in the EF and, similar to EF, is related to ventricular function. Besides RV functions, LV contractility was also affected. E, A, and DT were used for both ventricular diastolic function parameters. Tricuspid valve DT that was found to be prolonged in patients with PE and PAPm was similar in both groups.

Conclusion

We found that PE can lead to major cardiac problems, not limited only to the RV just below the defect; the LV systolic function also can be affected. We failed to demonstrate a relationship between the severity of PE and cardiac function. This possibly was due to the limited number of severe cases in our PE group. Clinicians should pay more attention even in mild PE cases due to the markedly affected cardiac functions in these individuals.

Study limitations: *In the current study most of the children had a mild and moderate form of the PE. Further studies with larger sample size and a greater number of children with a severe form of PE are warranted to better elucidate the cardiac functions in patients with PE.*

References

- Molik KA, Engum SA, Rescorla FJ, West KW, Scherer LR, Grosfeld JL. Pectus excavatum repair: experience with standard and minimal invasive techniques. *J Pediatr Surg* 2001; 36: 324-328.
- Blanco FC, Elliott ST, Sandler AD. Management of congenital chest wall deformities. *Semin Plast Surg* 2011; 25: 107-116.
- Williams AM, Crabbe DC. Pectus deformities of the anterior chest wall. *Paediatr Respir Rev* 2003; 4: 237-242.
- Fokin AA, Steuerwald NM, Ahrens WA, Allen KE. Anatomical, histologic, and genetic characteristics of congenital chest wall deformities. *Semin Thorac Cardiovasc Surg* 2009; 21: 44-57.
- Zhao L, Fenberg MS, Gaides M, Ben-Dov I. Why is exercise capacity reduced in subjects with pectus excavatum? *J Pediatr* 2000; 136: 163-167.
- Mocchegiani R, Badano L, Lestuzzi C, Nicolosi GL, Zanuttini D. Relation of right ventricular morphology and function in pectus excavatum to the severity of the chest wall deformity. *Am J Cardiol* 1995; 76: 941-946.
- Haller JA Jr, Peters GN, Mazur D, White JJ. Pectus excavatum: a 20-year surgical experience. *J Thorac Cardiovasc Surg* 1970; 60: 375-383.
- Jaroszewski DE, Warsame TA, Chandrasekaran K, Chaliki H. Right ventricular compression observed in echocardiography from pectus excavatum deformity. *J Cardiovasc Ultrasound* 2011; 19: 192-195.
- Park SY, Park TH, Kim JH, Baek HK, Seo JM, Kim WJ, et al. A case of right ventricular dysfunction caused by pectus excavatum. *J Cardiovasc Ultrasound* 2010; 18: 62-65.
- White JA, Fine NM, Shargall Y. Images in cardiovascular medicine. Pectus excavatum with compression of the inferior vena cava: a rare cause of recurrent syncope. *Circulation* 2009; 120: 1722-1724.
- Malek MH, Fonkalsrud EW, Cooper CB. Ventilatory and cardiovascular responses to exercise in patients with pectus excavatum. *Chest* 2003; 124: 870-882.
- Yalamanchili K, Summer W, Valentine V. Pectus excavatum with inspira-

- tory inferior vena cava compression: a new presentation of pulsus paradoxus. *Am J Med Sci* 2005; 329: 45-47.
13. Haller JA Jr, Loughlin GM. Cardiorespiratory function is significantly improved following corrective surgery for severe pectus excavatum. Proposed treatment guidelines. *J Cardiovasc Surg (Torino)* 2000; 41: 125-130.
 14. Quigley PM, Haller JA Jr, Jelus KL, Loughlin GM, Marcus CLL. Cardiorespiratory function before and after corrective surgery in pectus excavatum. *J Pediatr* 1996; 128: 638-643.
 15. Wynn SR, Driscoll DJ, Ostrom NK, Staats BA, O'Connell EJ, Mottram CD, et al. Exercise cardiorespiratory function in adolescents with pectus excavatum. Observations before and after operation. *J Thorac Cardiovasc Surg* 1990; 99: 41-47.
 16. Mosteller RD. Simplified calculation of body-surface area. *N Engl J Med* 1987; 22: 1098.
 17. Jaroszewski DE, Fonkalsrud EW. Repair of pectus chest deformities in 320 adult patients: 21 year experience. *Ann Thorac Surg* 2007; 84: 429-433.
 18. Bleeker GB, Steendijk P, Holman ER, Yu CM, Breithardt OA, Kaandorp TA, et al. Assessing right ventricular function: the role of echocardiography and complementary technologies. *Heart* 2006; 92 Suppl 1: 19-26.
 19. Sigalet DL, Montgomery M, Harder J. Cardiopulmonary effects of closed repair of pectus excavatum. *J Pediatr Surg* 2003; 38: 380-385.
 20. Gürsu AH, Karagün BS, Korkmaz O, Gürsu SS, Uçar MA. Correlation between Haller index and echocardiographic and spirometric findings in children with pectus excavatum. *Turk Kardiyol Dern Ars* 2014; 42: 259-264.
 21. Krueger T, Chassot PG, Christodoulou M, Cheng C, Ris HB, Magnusson L. Cardiac function assessed by transesophageal echocardiography during pectus excavatum repair. *Ann Thorac Surg* 2010; 89: 240-243.
 22. Bawazir OA, Montgomery M, Harder J, Sigalet DL. Mid-term evaluation of cardiopulmonary effects of closed repair for pectus excavatum *J Pediatr Surg* 2005; 40: 863-867.
 23. Malek MH, Berger DE, Housh TJ. Cardiovascular function following surgical repair of pectus excavatum; a meta analysis. *Chest* 2006; 130: 506-516.
 24. Lyons HA, Zuhdi MN, Kelly JJ Jr. Pectus excavatum ("funnel breast"), a cause of impaired ventricular distensibility as exhibited by right ventricular pressure pattern. *Am Heart J* 1955; 50: 921-922.
 25. Peterson RJ, Young WG Jr, Godwin JD, Sabiston DC Jr, Jones RH. Non-invasive assessment of exercise cardiac function before and after pectus excavatum repair. *J Thorac Cardiovasc Surg* 1985; 90: 251-260.
 26. Saleh RS, Finn JP, Fenchel M, Moghadam AN, Krishnam M, Abrazado M, et al. Cardiovascular magnetic resonance in patients with pectus excavatum compared with normal controls. *J Cardiovasc Magn Reson* 2010; 12: 73.
 27. Sutherland GR, Stewart MJ, Moran CM, Fleming A, Guell-Peris FJ, et al. Color Doppler myocardial imaging: a new technique for the assessment of myocardial function. *J Am Soc Echocardiogr* 1994; 7: 441-458.
 28. Gorcsan J 3rd, Strum DP, Mandarino WA, Gulati VK, Pinsky MR. Quantitative assessment of alterations in regional left ventricular contractility with color-coded tissue Doppler echocardiography: comparison with sonomicrometry and pressure-volume relations. *Circulation* 1997; 95: 2423-2433.
 29. Urheim S, Edvardsen T, Torp H, Angelsen B, Smiseth OA. Myocardial strain by Doppler echocardiography: validation of a new method to quantify regional myocardial function. *Circulation* 2000; 102: 1158-1164.
 30. Vogel M, Schmidt MR, Kristiansen SB, Cheung M, White PA, Sorensen K, et al. Validation of myocardial acceleration during isovolumic contraction as a novel noninvasive index of right ventricular contractility: comparison with ventricular pressure-volume relations in an animal model. *Circulation* 2002; 105: 1693-1699.
 31. Gürkan U, Aydemir B, Aksoy S, Akgöz H, Tosu AR, Öz D, et al. Echocardiographic assessment of right ventricular function before and after surgery in patients with pectus excavatum and right ventricular compression. *Thorac Cardiovasc Surg* 2014; 62: 231-235.

Received: 27/04/2016

Accepted: 24/05/2016

Published: 20/06/2016

Disclosure and conflicts of interest:

Conflicts of interest were not reported.

Corresponding author:

Dr. Esra Akyüz Özkan

Mail: uzdresra@gmail.com

A rare existence of paragangliomas Bilateral carotid body tumors: A case report

Sadi Kaplan¹, Tuğba Avcı¹, Çetin Murat Songur¹, Cavit Ceylan²

¹Yuksek Ihtisas Education and Research Hospital of Turkey, Department of Cardiovascular Surgery, Ankara, Turkey

²Yuksek Ihtisas Education and Research Hospital of Turkey, Department of Urology, Ankara, Turkey

Abstract

Carotid body tumors are rare paragangliomas and generally they have benign characters. Only 3% of all paragangliomas occur in the head and neck region. Surgical procedure of carotid body tumor has a high rate neurological morbidity because of a close communication with neurovascular formations. We report here a very rare case of glomus tumor threatened surgically.

Keywords: Carotid body tumor, bilateral, neurologic complication.

Kaplan S., Avcı T., Songur Ç.M., Ceylan C. A rare existence of paragangliomas; Bilateral carotid body tumors: A case report. EJCM 2016; 04 (2): 41-44. Doi: 10.15511/ejcm.16.00241.

Introduction

Carotid body tumors are rare paragangliomas and generally they have benign characters. They are originating in the paraganglionic cells of the carotid bifurcation. Their incidences are between 0.06 and 3.33 per 100,000 patient.⁽¹⁻²⁾ In most cases, paragangliomas are sporadic (75%) and %25 of them are associated with hereditary paraganglioma syndrome.⁽³⁾ Multifocal paragangliomas are rarely seen in sporadic cases (%10-20) but they have increasing tendency to be multifocal in familial form (%80).⁽⁴⁻⁵⁾

Generally cervical paragangliomas grow slowly, but if they left untreated, they grow rapidly due to rich vascular supply and expand encircling the vascular structure and cranial nerves. Surgery is the only curative treatment in this cases however surgical management of carotid body tumor has a high rate neurovascular morbidity because of a close communication with neurovascular formations. For the surgical planing and prognostic purposes, Shamblin classification was described for these tumors' size and invasion degree in 1971.⁽⁶⁾ We report here a very rare case of glomus tumor treated successfully with surgery.

Case Report

48 years-old male patient refered to us with the complain of bilateral painless huge neck masses. He had also obstructive sleep apne and hypopne syndrom leading to significant cyanosis for 2 years which was concurrent with neck masses. The masses diameters were 10,5x8cm on the left (**Picture 1**) side and 3x3cm on the right side.

Radiologic examination with USG, two and three dimentional CT (**Picture 2-3**) and MRI demonstrated glomus tumor in which were class 3 in Shamblin Classification. There was no hormonal activity or neurologic deficit about mass compression.

Material and Method

Three days after the embolization procedure he was operated on his left side. A huge tumoral mass which was tightly encircling the releated vessels was excised from all around the internal and external carotid arteries also like hypoglossus, vagus and laryngeus recur-

rens. There was no residuel mass. Histology confirmed the diagnosis of glomus tumor.

Surgery was uncomplicated. He was moved to service bad on the next day and discharged 10 days after the surgery. A mild apathy and aphasia were occured on second day of the surgery.he was cosultated to the neurology department. With corticosteroid theraphy, the symptoms were regressed on 4. day and disapperared on 8. day. He was checked on the first month of the surgery. There were no permanent operative cranial nerve injuries and other problems about surgery. His right side surgery will be applied in a few months.

Conclusion


Carotid body tumors are very rare neoplasms and rarely seen in neck resion. In this cases, generally, clinical follow-up is advised untill the compression or hormonal activation signs due to mass were occured. Reported nerve injury rates range from 11% to 50%^(7,8, 9,10) and has high risks with higher Shamblin class. ⁽¹⁾ Neuronal injuries (transient or permanent) of the vagus nerve, hypoglossal nevre and other communicated nerves and vascular injuries of the carotid artery and it's branches and surrounding veins have been associated with surgical procedure⁽⁸⁾, especially in larger tumors with close proximity to critical structures requiring a more complex procedure for removal.



Picture 1

Results

Surgery is the only curative therapy and accepted as a gold standart despite high risks for neurovascular complications.



Picture 2



Picture 3

References

1. Sajid MS, Hamilton G, Baker DM. A multicentre review of carotid body tumour management. *Eur J Vasc Endovasc Surg.* 2007; 34 (2):127-30.
2. Plukker JT, Brongers EP, Vermey A, Krikke A, van den Dungen JJ. Outcome of surgical treatment for carotid body paraganglioma. *Br J Surg.* 2001;88(10):1382-6.
3. Dixon JL, Atkins MD, Bohannon WT, Buckley CJ, Lairmore TC. Surgical management of carotid body tumors: a 15-year single institution experience employing an interdisciplinary approach *Proc (Bayl Univ Med Cent).* 2016 Jan;29(1):16-20.
4. Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. *Cancer.* 2002;94:730-7
5. Boeckder CC, Ridder GJ, Schipper J. Paragangliomas of the head and neck: diagnosis and treatment. *Fam Cancer.* 2005;4:55-9.
6. Shamblin WR, Remine WH, Sheps SG, Harrison EG. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. *Am J Surg* 1971;122(6):732-739
7. Del Guercio L, Narese D, Ferrara D, Butrico L, Padricelli A, Porcellini M. Carotid and vagal body paragangliomas. *Transl Med UniSa* 2013;6(6):11- 15
8. Luna-Ortiz K, Rascon-Ortiz M, Villavicencio-Valencia V, Granados-Garcia M, Herrera-Gomez A. Carotid body tumors: review of a 20-year experience. *Oral Oncol* 2005;41(1):56-61.
9. Neskey DM, Hatoum G, Modh R, Civantos F, Telischi FF, Angeli SI, Weed D, Sargi Z. Outcomes after surgical resection of head and neck paragangliomas: a review of 61 patients. *Skull Base* 2011;21(3):171-176.
10. Davidovic LB, Djukic VB, Vasic DM, Sindjelic RP, Duvnjak SN. Diagnosis and treatment of carotid body paraganglioma: 21 year experience at a clinical center of Serbia. *World J Surg Oncol* 2005;3(1):10.

Received: 29/03/2016

Accepted: 08/05/2016

Published: 20/06/2016

Disclosure and conflicts of interest:

Conflicts of interest were not reported.

Corresponding author:

Dr. Sadi Kaplan

Mail: skpn1966@hotmail.com

May the extraction of fresh thrombus prevent no-reflow phenomenon in coronary artery bypass surgery?

Ertan Demirdaş¹, Kıvanç Atılgan¹, Ferit Çiçekçiođlu¹

¹ Bozok University Research and Application Hospital and Cardiovascular Surgery, Assist. Prof., Yozgat, Turkey

Abstract

The most frequent reason of acute coronary syndrome is the occlusion of coronary artery with thrombus due to the rupture of the plaque in it. Treatment involves medical treatment, percutaneous coronary interventions and coronary artery bypass grafting (CABG). In CABG the revascularization of the coronary artery and, if necessary, the extraction of thrombus may be lifesaving.

Keywords: Thrombus, acute coronary syndrome, coronary artery bypass

Demirdaş E., Atılgan K., Çiçekçiođlu F. May the extraction of fresh thrombus prevent no-reflow phenomenon in coronary artery bypass surgery? EJCM 2012; 04 (2): 45-48. DOI: 10.15511/ejcm.16.00245.

Introduction

The most frequent reason for the acute coronary syndrome (ACS) is the occlusion of the coronary artery with the thrombus due to the rupture of the plaque in the coronary artery.⁽¹⁾ The cure involves medical treatment, percutaneous coronary interventions (PCI) and coronary artery bypass grafting (CABG).⁽²⁻⁴⁾ Concisely, medical treatments are anti-ischaemic, anti-thrombotic and fibrinolytic treatments. PCI has a very important position in ACS as a well accepted and spreading process. PCI enables both the stabilization of the ruptured plaque and the resolution of the thrombus in the coronary artery. Revascularization of the totally occluded coronary artery due to the rupture of a plaque and the extraction of the thrombus, during CABG being performed under emergent circumstances, provides us to have pleasing results in morbidity and mortality.

Case History

A 37-year old male without a history of an accompanying illness or drug utilization was referred to our clinic with a severe chest pain. Having the results of inferior ST elevations in the electrocardiogram and troponin I:21 ng/ml in biochemical tests, 600 mg of Clopidogrel orally and 10000 Units of Enoxaparine subcutaneously

were applied to the patient. Three vessel disease and a filling defect in the right coronary artery compatible with thrombus were observed in coronary angiography. The patient with unstable angina underwent an emergent CABG on the fourth hour of chest pain.

Operating Procedure

The patient was operated under emergent circumstances. Following median sternotomy, saphenous vein grafts and left internal mammary arteries (LIMA) were harvested. After having cardiac arrest with a-egrade and retrograde cold crystalloid cardioplegia, arteriotomy was applied on the distal body of the right coronary artery, just before the bifurcation of the posterior descending artery and the posterolateral artery.

We observed a fresh thrombus and a thrombectomy process was applied with a 2F Fogarty catheter (**Figure 1, 2**). Then, right coronary artery bypass was applied with the saphenous vein graft. LIMA was anastomosed to the left anterior descending artery and the other part of the saphenous vein graft was anastomosed to the optional diagonal and obtus marginalis arteries sequentially. After decannulation and the neutralization of heparin with prothrombin, tranexamic acid was infused with a dose of 15 mg/kg. The patient

Figure 1. Fresh thrombus is seen after coronary incision





Figure 2. The embolectomy of fresh thrombus



was discharged on the postoperative fourth day.

Discussion

Soft plaques are pathologies with a high risk of rupture resulting with the acute occlusion of the coronary artery and, hence, ACS compelling the patient to face serious fatal complications. Thus, ACS has an important place among the coronary artery diseases. Despite the early diagnosis and the provision of TIMI 3 flow after the revascularization with even CABG or PCI, sometimes, it may be possible to observe the persistence of the myocardial ischaemia.

It is not uncommon having insufficient myocardial response, haemodynamic instability resulting with the initiation of positive inotropic drug and intraaortic ballon pump treatments despite the successful coronary artery bypassing and effective heart protecting techniques. This situation is called as “No-reflow phenomenon”, which is a conclusion of multiple factors

as microvascular spasm, thrombus load, endothelial dysfunction, inflammatory neutrophil activation, interstitial edema and embolization.⁽⁵⁻⁷⁾

The distal embolization of the microparticulas of fresh thrombus in the coronary artery having a soft plaque anatomy is the main point of the pathophysiology in this process. The mortality rate has a ten fold increase in the patients having no-reflow phenomenon in comparison with the ones not having no-reflow phenomenon.⁽⁸⁻¹⁰⁾ Thus, in this case we preferred to extract the fresh thrombus in the coronary artery.

As a result, we believe that among the patients undergoing emergent CABG due to ACS inflicting because of the acute rupture of soft plaque and total occlusion of the artery with fresh thrombus, bypassing the coronary arteries after the extraction of the fresh thrombus would save better mortality and morbidity rates and survey.

References

1. Mackman N. Triggers, targets and treatments for thrombosis. *Nature* 2008;451:914–8.
2. Overbaugh KJ. Acute coronary syndrome. *Am J Nurs* 2009;109:42–52.
3. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32:2999–3054.
4. Van de Werf F, Bax J, Betriu A et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 2012;33:2569-619.
5. Shereif Rezkalla, Robert A. Kloner. No-reflow phenomenon: current perspective. *Circulation*. 2002;105:656-662.
6. Manciet LH, Poole DC, McDonagh PF, et al. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. *Am J Physiol* 1994;266:H1541-50.
7. Yip HK, Chen MC, Chang HW, Hang CL, Hsieh YK, Fang CY, Wu CJ. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. *Chest* 2002; 122(4): 1322-1332. 81. Schroder R: ST segment resolution on 12-lead ECG. *Circulation* 2004
8. Kitazume H, Iwama T, Kubo H, et al. No-reflow phenomenon during percutaneous transluminal coronary angioplasty. *Am Heart J* 1988;116:211-5.
9. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of no-reflow after percutaneous coronary intervention. *Circulation* 1994;89:2514-8.
10. Abbo KM, Dooris M, Glazier S, et al. No-reflow after percutaneous coronary intervention: Clinical and angiographic characteristics, treatment and outcome. *Am J Cardiol* 1995;75:778-82.

Received: 15/03/2016

Accepted: 22/05/2016

Published: 20/06/2016

Disclosure and conflicts of interest:

Conflicts of interest were not reported.

Corresponding author:

Dr. Kıvanç Atılğan

Mail: kivancatilgan@gmail.com

E-Journal of Cardiovascular Medicine welcomes scientific contributions in the field of cardiovascular and thoracic surgery - all aspects of surgery of the heart, vessels and the chest in various article types: new ideas, brief communications, work in progress, follow-up studies, original articles, best evidence topics, case reports, reports on unexpected results etc. All manuscripts shall be reviewed by the Editor-in-Chief, Associate Editors, Invited Referees and a Statistician when appropriate. If accepted, articles will be posted online and opened up for discussion. Acceptance criteria are based on the originality, significance, and validity of the material presented.

All material to be considered for publication in E-Journal of Cardiovascular Medicine should be submitted in electronic form via the journal's online submission system. (<http://my.ejmanager.com/ejcm/>)

A cover letter should be enclosed to all new manuscripts (to be filled in online), specifying the name of the journal and the type of paper, and including the following statements:

- The manuscript should not be previously published in print or electronic form and is not under consideration by another publication.
- All authors should contribute to the content of the article.
- All authors should read and approve the submission of the manuscript to ICVTS.
- Subject to acceptance, authors will sign an exclusive license to publish.
- No ethical problem or conflict of interest should exist.

If your first language is not English, we recommend that you consult an English language editing service to ensure that the academic content of your paper is fully understood by journal editors and reviewers. Language editing does not guarantee that your manuscript will be accepted for publication.

Manuscripts should be prepared using a word-processing package (save in .doc, .docx or .rtf format). The font type and font size should preferably be Arial or Times New Roman 11 points. The manuscript should be double-spaced and should include line and page numbers. The lines of the reference list do not need to be numbered; include a section break before.

Manuscripts should be organized as follows:

(a) Title page; (b) Abstract and Key words; (c) Text with the following sections (not applicable for article types with unstructured abstracts): Introduction, Materials and Methods, Results, Discussion, Acknowledgement (optional), Funding statement, Conflict of interest statement, (d) Figure (and Video) legends; (e) Tables; (f) References.

Title page (1st page): Title: should be brief and descriptive (100 characters) - no abbreviations are allowed, even if well known.

Authors: list all authors by full first name, initial of or full middle name and family name. Qualifications are not required. Ensure the author names correspond (in spelling and order of appearance) with the metadata of the system

Institution(s): include the name of all institutions with the location

(department, institution, city, country) to which the work should be attributed (in English). Use superscript numbers to connect authors and their department or institution.

Corresponding author: The full name, full postal address, telephone/fax numbers and the e-mail address should be typed at the bottom of the title page.

Meeting presentation: If the manuscript was (or will be) presented at a meeting, include the meeting name, venue, and the date on which it was (or will be) read; also indicate if you have submitted an Abstract of this manuscript for the EACTS or ESTS annual meeting and whether it has been accepted (if known).

Word count: The total number of words of the whole article (including title page, abstract, main text, legends, tables and references) must be specified on the title page.

Abstract (2nd page): An abstract should be a concise summary of the manuscript. Reference citations are not allowed. The abstract should be factual and free of abbreviations, except for SI units of measurement.

Keywords: Following the abstract, 3-6 keywords should be given for subject indexing.

Introduction: Should state the purpose of the investigation and give a short review of pertinent literature.

Materials and methods: Should be described in detail with appropriate information about patients or experimental animals. Use of abbreviations renders the text difficult to read; abbreviations should be limited to SI units of measurement and to those most commonly used, e.g. VSD, ASD, CABG (abbreviations should not be included in headings and extensions should be included at first mention).

Results: Results should be reported concisely and regarded as an important part of the manuscript. They should be presented either in tables and figures, and briefly commented on in the text, or in the text alone. Repetition of results should be avoided!

Discussion: The discussion is an interpretation of the results and their significance with reference to pertinent work by other authors. It should be clear and concise.

Acknowledgement: Acknowledgements and details of non-financial support must be included at the end of the text before the references. Personal acknowledgements should precede those of institutions or agencies.

Tables: All tables must be included in the manuscript file, should start on separate pages and be accompanied by a title, and footnotes where necessary. The tables should be numbered consecutively using Arabic numerals. Units in which results are expressed should be given in parentheses at the top of each column and not repeated in each line of the table.

References: Authors are responsible for checking the accuracy of all references. If you use EndNote or Reference Manager to facilitate referencing citations (not required for submission), this journal's style is available for use. References should be numbered in order of appearance in the text (in Arabic numerals in parentheses) and must be listed numerically in the reference list. Journal titles and author initials should be properly abbreviated and punctuated.

GENERAL RULES

Files should be prepared as a Word document using font size 12 Times New Roman characters, double-spaced and with 2.5 cm margins on each side, top and bottom. Only standard abbreviations should be used; other shortened phrases should be indicated in parentheses as used in the text. Generic or chemical names of drugs should be used instead of trade names.

ETHICAL ISSUES

Publishing responsibilities of authors and Ethics

The publication of an article in a peer-reviewed journal is an essential building block in the development of a coherent and respected network of knowledge. It is a direct reflection of the quality of work of the author and the institutions that support them. Peer-reviewed articles support and embody the scientific method. It is therefore important to agree upon standards of expected ethical behavior.

Reporting standards

Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review and professional publication articles should also be accurate and objective, and editorial 'opinion' works should be identified as such.

Hazards and human or animal subjects

If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) has approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

Use of patient images or case details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to us on request. Particular care should be taken with obtaining consent where children are concerned (in particular where a child has special needs or learning disabilities), where an individual's head or face appears, or where reference is made to an individual's name or other personal details.

Originality and plagiarism

The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of

others, that this has been appropriately cited or quoted. Plagiarism takes many forms, from 'passing off' another's paper as the author's own paper, to copying or paraphrasing substantial parts of another's paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable.

Data access and retention

Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

Multiple, redundant or concurrent publication

An author should not in general publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. In general, an author should not submit for consideration in another journal a previously published paper. Publication of some kinds of articles (e.g. clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication.

Acknowledgement of sources

Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in those services.

Fundamental errors in published works

When an author discovers a significant error or inaccuracy in his/her own published work, it is the author's obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper. If the editor or the publisher learns from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.

Authorship of the paper

Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant

contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts. Before the accepted manuscript is published in an online issue:

Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager by the corresponding author of the accepted manuscript, and must include:

The reason the name should be added or removed, or the author names rearranged

Written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed

Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure described above.

Note that:

- Journal Managers will inform the Journal Editors of any such requests
- Publication of the accepted manuscript in an online issue is suspended until authorship has been agreed
- After the accepted manuscript has been published in an online issue:

Any requests to add, delete or rearrange author names in an article published in an online issue will follow the same policies as noted above and may result in a corrigendum.

TYPES OF PAPERS

Original Articles

Original articles should consist of sections titled as “Abstract, Introduction, Materials and Methods, Results, Discussion and Conclusion”. For information about the abstract, refer to ‘Manuscript Formatting’ section.

The Introduction section of the manuscript should clearly state the purpose of the manuscript and include a brief summary of the most relevant national and international literature stating the main purposes and research question of the study. Contradictory aspects of the research, if present, should be mentioned. The expected contribution of this study to family medicine and practice should be highlighted.

The Materials and Methods section should describe the study population and the study design, with adequate information on the

techniques, materials and methods used. The section should include information of the study type, population, sample, sample size and selection of the sample. Validity and reliability of scales and questionnaires used also should be referred to. A clear description of the statistical methods should also be given.

The Results section should include a detailed report on the findings of the study. All figures, tables and illustrations should be used in this section. Results should be presented either as text or figures and/or tables and not be replicated.

The Discussion section of the study should emphasize the importance of the results and compare them with the results of other authors with relevant citations from the most recent literature. Study limitations and strengths should be specified. Suggestions for further studies in this area should be added.

The Conclusion should include the main conclusions based on the results of the research, emphasize the contributions of the study to family practice and propose original suggestions. A brief revision of all the results and the discussion should be avoided.

Original articles excluding case reports and systematic reviews should not exceed 3000 words excluding the abstract, references and tables. Case reports should not exceed 1000 words excluding the abstract, references and tables. There are no restrictions for systematic reviews.

Short Reports

Short Reports are accepted when the research topic, aim and results of the study are limited in scope and in cases that do not require writing a full original article. Short Reports can be described as a summarized version that have been prepared according to the structure of research articles. Publishing an article as a short report does not reflect a lower quality. The same rules as relevant to original articles apply to preparing a short report, but structured abstracts are not mandatory references and tables should not exceed 6 and 2 in number, respectively. Abstracts should not exceed 100 words and the text should be restricted to a maximum of 1000 words.

Reviews

Reviews are evidence-based articles about a specific topic using relevant citations from the most recent literature with the authors’ conclusions on this subject. The author is expected to have conducted research on the subject and to have experience in order to discuss and analyze the subject. There is no obligation to follow a particular format and may contain subtitles depending on the subject. The text should not exceed 4000 words excluding the title, abstracts, references and tables. E Journal of Cardiovascular Medicine, only publishes review articles solicited by the editors.

Letters to Editor and Comments

Letters to the editor or comments can be sent to provide commentary and analysis concerning an article published in the journal, to give information about ongoing research, to provide informa-

tion in cardiology and cardiovascular-vascular-endovascular surgery, cardio-metabolic and vascular sciences. Letters to the editor or comments may include an optional title, tables and references. These articles should not exceed 1000 words.

What Would You Do?

These are brief articles discussing cases and situations encountered in cardiology and cardiovascular surgery with a biopsychosocial approach. If necessary, photographs (with permission from the patient/owner) may be added. Sections should consist of a title, case report, discussion, questions and answers. Brief comments can be sent to provide commentary on previous articles and case reports written by other authors. Comments should include the number of the journal the article was published in. The text should not exceed 1000 words.

International Reprints

Translations of important documents, declarations and guidelines prepared by international organizations in the field of cardiology and cardiovascular surgery, may be published in the journal. Presubmission Inquiry to the Editorial Board of the Journal before submitting the article is recommended. It is the translator's responsibility to obtain permission from the owner of the original manuscript for publication and translation.

News

These articles focus on advances and innovations in clinical topics relevant to cardiology and cardiovascular surgery. There is no obligation to follow a particular format. The text should be limited to 1000 words.

Editorials

Editorials usually provide information about the editorial policy of E Journal of Cardiovascular Medicine, give commentary and feedback on articles published in the journal, draw attention to topics of current interest and give information related to and discuss the development of cardiology and cardiovascular surgery in the world. They are mainly written by the members of the Editorial Board. Editorials are limited to 2000 words with some exceptions and may include a title and references when necessary.

MANUSCRIPT FORMATTING

Manuscripts should be designed in the following order:

Title page

Abstract

Main text

References

Tables, figures and illustrations

Title Page

The title page of the manuscript should include: The title, first

and last names of each author. Complete affiliation and title for each author, with the name of department (s) and institution (s) to which the work should be attributed.

The corresponding author should be clearly identified with name, address, telephone- facsimile number and email address for correspondence about the manuscript. Authors should clearly indicate if the article has previously been presented at a congress or scientific meeting. The title should be concise and informative without abbreviations and not exceed 10 words.

Abstract

Abstracts should be exact in English, with a minimum of 150 and maximum of 350 words. Abstracts of original research articles should be structured under subheadings as follows: objectives, methods, results and conclusion. A maximum of 3 key words should be added to English abstracts.

Text

The text contains the rest of the manuscript. It is structured differently according to the type of manuscript (original research article, review, etc.). For example, original research articles should consist of aim and objectives, methods, results, discussion and conclusion.

References

References should be cited in consecutive numerical order as first mentioned in the text and designated by the reference number in parentheses. If the number of authors for the reference is more than 6 authors, list the first three authors and add "et al".

Journal names should be abbreviated as used in Index Medicus. References should be cited in the Vancouver style. For detailed information please visit the relevant link

Examples:

For research articles follow the example below:

– Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality. JAMA 1995; 274(2): 131–6.

For book chapters follow the example below:

– Rakel RE. The family physician. In: Rakel RE, editor. Textbook of family practice. 5th ed. Philadelphia: W.B. Saunders; 1995. p. 3-19.

For web pages follow the example below:

– Guidance for clinicians. An International Benchmarking Study. <http://www.who.int/topics/surgery/> accessed: 29/09/2002.

Tables and Figures

Legends should take place on the top of the page for tables, and bottom of the page for figures and placed on separate pages. Explain all nonstandard abbreviations in footnotes.



E Journal of Cardiovascular Medicine
is a global e-journal targeting articles on:

- clinical cardiology,
- interventional cardiology,
 - arrhythmia,
- cardiovascular surgery,
- vascular & endovascular surgery,
- vascular biology